Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections

Angelique E Boutzoukas,Natalie Mackow,Abhigya Giri,Lauren Komarow,Carol Hill,Liang Chen,Yohei Doi,Michael J Satlin,Cesar Arias,Minggui Wang,Laura Mora Moreo,Erica Herc,Eric Cober,Gregory Weston,Robin Patel,Robert A Bonomo,Vance Fowler,David van Duin,Antibacterial Resistance Leadership Group,MDRO Network Investigators,Ritu Banerjee,Helen Boucher,Henry 'Chip' Chambers,Sara Cosgrove,Heather Cross,Sarah Doernberg,Dennis Dixon,Scott Evans,Varduhi Ghazaryan,Toshi Hamasaki,Kim Hanson,Anthony Harris,Thomas Holland,Ebbing Lautenbach,Tom Lodise,Maureen Mehigan,Kyung Moon,David Paterson,Melinda Pettigrew,Erica Raterman,Tamika Samuel,Sam Shelburne,Lanling Zou,Souha S Kanj,Jean Francois Jeff Jabbour,Fujie Zhang,Judith J Lok,Robert A Salata,Martin Stryjewski,Valentina Di Castelnuovo,Jose Millan Oñate Gutierrez,Susan Richter,Deverick J Anderson,Beth Evans,Heather R Cross,Keri Baum,Rebekka Arias,Vance G Fowler,Karen Ordoñez,Jesse T Jacob,Linghua Li,Barry N Kreiswirth,Claudia Manca,Samit Desai,Ezequiel Cordova,Maria Rioseco,Samuel Vichez,Marisa L Sanchez,Sandra Valderrama,Jairo Figueroa,Cesar A Arias,An Q Dinh,Diane Panesso,Kirsten Rydell,Truc T Tran,Fupin Hu,Jiachun Su,Jianping Jiang,Xiaogang Xu,Yang Yang,Jose M Munita,Maria Spencer,Thamer Alenazi,Steven H Marshall,Susan D Rudin,Charles Huskins,Kerry,Sara Revolinski,Glenn Wortmann,Robert C Kalayjian,Greg Weston,Belinda Ostrowsky,Gopi Patel,Daniel Eiras,Angela Kim,Julia Garcia-Diaz,Soraya Salcedo,John J Farrell,Zhengyin Liu,Andrew Henderson,David L Paterson,Qing Xie,Keith S Kaye,Hainv Gao,Yunsong Yu,Mary Waters,Bettina C Fries,Brandon Eilertson,Kalisvar Marimuthu,Kean Lee Chew,Nares Smitasin,Paul Ananth Tambyah,Jason C Gallagher,Anton Peleg,Marcel Leroi,Lanjuan Li,Lizhao Ge,Todd McCarty,Henry F Chambers,Omai B Garner,Lilian M Abbo,Jennifer H Han,Darren Wong,Blake Hanson,Jinnethe Reyes,Maria Virginia Villegas Botero,Lorena Diaz,Federico Perez,Sorabh Dhar,Zhiyong Zong

DOI: https://doi.org/10.1093/jac/dkae306

2024-09-05

Abstract:Background: The CDC reported a 35% increase in hospital-onset (HO) carbapenem-resistant Enterobacterales (CRE) infections during the COVID-19 pandemic. We evaluated patient outcomes following HO and community-onset (CO) CRE bloodstream infections (BSI). Methods: Patients prospectively enrolled in CRACKLE-2 from 56 hospitals in 10 countries between 30 April 2016 and 30 November 2019 with a CRE BSI were eligible. Infections were defined as CO or HO by CDC guidelines, and clinical characteristics and outcomes were compared. The primary outcome was desirability of outcome ranking (DOOR) 30 days after index culture. Difference in 30-day mortality was calculated with 95% CI. Results: Among 891 patients with CRE BSI, 65% were HO (582/891). Compared to those with CO CRE, patients with HO CRE were younger [median 60 (Q1 42, Q3 70) years versus 65 (52, 74); P < 0.001], had fewer comorbidities [median Charlson comorbidity index 2 (1, 4) versus 3 (1, 5); P = 0.002] and were more acutely ill (Pitt bacteraemia score ≥4: 47% versus 32%; P < 0.001). The probability of a better DOOR outcome in a randomly selected patient with CO BSI compared to a patient with HO BSI was 60.6% (95% CI: 56.8%-64.3%). Mortality at 30-days was 12% higher in HO BSI (192/582; 33%) than CO BSI [66/309 (21%); P < 0.001]. Conclusion: We found a disproportionately greater impact on patient outcomes with HO compared to CO CRE BSIs; thus, the recently reported increases in HO CRE infections by CDC requires rigorous surveillance and infection prevention methods to prevent added mortality.